pharmaphorum

NOVEMBER 16, 2020

She first joined the EMA in 2002 and filled a number of senior roles at the regulator including head of inspections, head of international liaison and head of international affairs before switching to the WHO in 2016. Emer Cooke.

Vaccines 64

Vaccines Packaging FDA 64

The Checkup by Singlecare

NOVEMBER 30, 2023

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. However, studies have concluded that using acetaminophen after vaccination to treat fever or pain did not affect antibody response.

Immunization 98

Immunization Vaccines FDA Labelling 98

pharmaphorum

FEBRUARY 26, 2021

Weldon became the Chairman and CEO of J&J in 2002. J&J’s size meant that it had the resources to bring to bear against COVID-19 as the pandemic ravaged the world in 2020 and 2021, and the company soon began work on its own vaccine in partnership with the US government. billion the following February.

Vaccines 126

Vaccines Communication Labelling 126

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Medical Records 116

Medical Records Vaccines Hospitals 116

pharmaphorum

OCTOBER 12, 2021

The 59-year-old physician worked at J&J’s Janssen pharma unit in the 1990s, and re-joined the group when it acquired Virco and Tibotec in 2002, two companies of which he was CEO and chairman, respectively, to expand its HIV drug pipeline. billion in 2010.

Vaccines 52

Vaccines 52

pharmaphorum

DECEMBER 2, 2020

Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009, and Medivation in 2016. The era of mega-mergers.

Compounding 128

Compounding Vaccines Pharmaceutical Companies Pharmaceutical Companies 128

ISPE

AUGUST 7, 2023

Cooke, who has over 30 years of experience in international regulatory affairs, with 18 years in leadership roles, took the helm at EMA as director in November 2020, early in the pandemic, after having worked at EMA since 2002, serving as head of inspections initially and then as head of international affairs from 2009 to 2016.

Vaccines 52

Vaccines Communication 52

The Checkup by Singlecare

JUNE 7, 2024

Humira is a biologic drug and a monoclonal antibody that the FDA approved in 2002. While taking Cyltezo or Humira, you should not get live vaccines. Check with a healthcare provider or pharmacist before getting any vaccines. Biologics come from natural sources like animals or humans and may be produced with biotechnology.

Vaccines 52

Vaccines Insurance FDA Insurance Coverage 52

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. Diaz has been with Almirall since 2002, most recently serving as senior director of corporate strategy.

Immunization 52

Immunization Vaccines 52

PharmaShots

APRIL 25, 2023

R&D Expenditure: $883M Founded Year: 2002 Total Employees: ~2000 Headquarters: Massachusetts, United States Market Cap: $25.4B The company strives to discover and develop therapeutic products under its business segments, including General Medicines, Specialty Medicines, and Vaccines. R&D Expenditure: $6.6B

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

ISPE

AUGUST 30, 2022

During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. Published 2002.

Documentation 52

Documentation FDA Packaging Communication 52